Piper Jaffray downgrades Optimer Pharmaceuticals (Nasdaq: OPTR) from Overweight to Neutral and cuts the price target from $17 to $10 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE